<SEC-DOCUMENT>0001437749-20-006025.txt : 20200324
<SEC-HEADER>0001437749-20-006025.hdr.sgml : 20200324
<ACCEPTANCE-DATETIME>20200324164103
ACCESSION NUMBER:		0001437749-20-006025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200324
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200324
DATE AS OF CHANGE:		20200324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		20738900

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20200323_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head>
	<title>dffn20200323_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 3/24/2020 8:30:01 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>UNITED STATES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">________________</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>FORM 8-K</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>CURRENT REPORT</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">_________________</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (Date of earliest event reported): </b><b>March </b><b>24</b><b>, 2020</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">___________________</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:33.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>000-24477</b></p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of incorporation)</p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number)</p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:42.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>1317 Carlton Avenue, Suite 200</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Charlottesville, Virginia</b></p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>22902</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(434) 220-0718</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Not applicable</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:0.1%;width:99.9%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); width: 33.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Title of each class</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-top: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Trading Symbol(s)</p>
			</td>
			<td style="vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); width: 33.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:33.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">DFFN</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>&#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</b>&#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item </b><b>8</b><b>.01 </b><b>Other Events</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On March 24, 2020, Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing that the Company anticipates enrollment in its ambulance-based stroke trial will be slowed due to the impact of the coronavirus. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item&nbsp;9.01 &#8211; Financial Statements and Exhibits</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(d) Exhibits </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="ex_178686.htm" style="-sec-extract:exhibit;">Press release issued March 24, 2020</a></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>SIGNATURES</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Dated: March 24, 2020&nbsp;&nbsp;</p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>David G. Kalergis</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Name:</p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;">David G. Kalergis</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Title:</p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;">Chief Executive Officer</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_178686.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_178686.htm</title>

	<!-- Generated by ThunderDome Portal - 3/24/2020 6:07:00 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:left;text-indent:0pt;"><b>&nbsp;</b><img alt="" src="logo.jpg"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Diffusion Pharmaceuticals</b><b> Anticipates Enrollment in its Ambulance-based Stroke Trial </b><b>Will </b><b>be </b><b>Slowed Due </b><b>to the Impact of the Coronavirus</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>Overtaxed healthcare systems </i><i>will</i><i> delay enrollment in some geographic locations</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>CHARLOTTESVILLE, Va. (</b><b>March</b><b> </b><b>24</b><b>, 2020</b><b>) &#8211; Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)</b> (&#8220;Diffusion&#8221; or &#8220;the Company&#8221;), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body&#8217;s ability to bring oxygen to the areas where it is needed most, today announced that it expect delays in enrollment in the Company&#8217;s ambulance-based PHAST-TSC phase 2 clinical trial in acute stroke due to the coronavirus. The LA County Fire Department has informed us that, due to the necessity to respond to the pandemic, it is suspending future training of first responders who had been scheduled to participate in the trial protocol. Such disruptions are expected to delay the Company&#8217;s previously announced timeline for study completion.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#8220;The coronavirus pandemic is affecting the conduct of clinical trials throughout the world, and the PHAST-TSC program is no exception,&#8221; said Diffusion&#8217;s CEO, David Kalergis, JD/MBA. &#8220;We are following the FDA&#8217;s recent guidelines for conducting clinical trials during this emergency, and are planning ways to make up lost time once the pandemic abates.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body&#8217;s ability to bring oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion&#8217;s lead drug TSC was originally developed in conjunction with the Office of Naval Research, which was seeking a way to treat hemorrhagic shock caused by massive blood loss on the battlefield.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Evolutions in research have led to Diffusion&#8217;s focus today: Fueling Life by taking on some of medicine&#8217;s most intractable and difficult-to-treat diseases, including stroke, GBM brain cancer and respiratory distress. In each of these diseases, hypoxia &#8211; oxygen deprivation of essential tissue in the body &#8211; has proved to be a significant obstacle for medical providers and is the target for TSC&#8217;s novel mechanism. The Company is currently enrolling patients in its PHAST-TSC phase 2 clinical trial in acute stroke. In July 2019 the Company reported favorable safety data in a 19-patient dose-escalation run-in study to its Phase 3 INTACT program, using TSC to target inoperable GBM. Further findings from the dose-escalation run-in study, released in December 2019, also showed possible signals of enhanced survival and patient performance.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Preclinical data supports the potential for TSC as a treatment for other conditions where hypoxia plays a major role, such as myocardial infarction, peripheral artery disease, and neurodegenerative conditions such as Alzheimer&#8217;s and Parkinson&#8217;s disease. In addition, RES-529, the Company&#8217;s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Diffusion is headquartered in Charlottesville, Virginia &#8211; a hub of advancement in the life science and biopharmaceutical industries &#8211; and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div style="margin: 0pt;"><img alt="" src="logo.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Forward-Looking Statements</b></p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion&#8217;s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: Diffusion&#8217;s ability to maintain its Nasdaq listing, market conditions, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; general business and economic conditions; the sufficiency of the company&#8217;s cash, the company's need for and ability to obtain additional financing or partnering arrangements; and the various risk factors (many of which are beyond Diffusion&#8217;s control) as described under the heading &#8220;Risk Factors&#8221; in Diffusion&#8217;s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Contacts:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">David Kalergis, CEO</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Diffusion Pharmaceuticals Inc.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(434) 825-1834</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>dkalergis@diffusionpharma.com</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">or</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">LHA Investor Relations</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Kim Sutton Golodetz</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(212) 838-3777</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>kgolodetz@lhai.com</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"># # #</p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MZ1J]QX;TN;Q7=0WR6-IIL^K7UW?BQ1_(2=W><?SO_P#!0?\ ;._9J_;_ /\
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MK-[KXJ6(LM2UB)#>7L36VEZ=:K"Q;,5G;Q@?(,_7G_!PE^P'^TM_P4,_9?\
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M\('I7C^_C^(OQ?D\3>$9?&-QX?U9I]0T?2+^W:6#0KO3M5TNUUXW#7"?:8&
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MFMM'O_$FFZ%8:C$8].4ZG:SS:)(+;;^-G[./QC;XT?\ !2#Q=9_L[_$3QO\
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
